Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Payables (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Payables for 4 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Payables rose 105.33% to $1.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.4 million, a 105.33% increase, with the full-year FY2024 number at $1.0 million, up 99.05% from a year prior.
  • Payables was $1.4 million for Q3 2025 at 60 Degrees Pharmaceuticals, up from $905813.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $17.6 million in Q4 2022 to a low of $506206.0 in Q4 2023.
  • A 4-year average of $2.6 million and a median of $1.0 million in 2024 define the central range for Payables.
  • Peak YoY movement for Payables: crashed 97.13% in 2023, then skyrocketed 118.71% in 2025.
  • 60 Degrees Pharmaceuticals' Payables stood at $17.6 million in 2022, then plummeted by 97.13% to $506206.0 in 2023, then surged by 99.05% to $1.0 million in 2024, then surged by 38.08% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Payables are $1.4 million (Q3 2025), $905813.0 (Q2 2025), and $1.2 million (Q1 2025).